FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

ALGN

Align TechnologyNASDAQ · Health Care Supplies · Health Care
Previous close
149.89
Change
−3.82 / −2.49%
FinDog View
Neutral
52-Week Range ?
130.23 – 200.44
P/E (TTM) ?
25.6
Sector median 29.5
Forward P/E ?
12.6
Based on consensus earnings for the next 12 months
Market Cap
$10.5B
1M
+3.12%
S&P 500 −0.91% over same period
Volume / Avg Volume
1.1M / 1.1M
1.05× average
Latest earnings analysisFY2026 Q2Reported 2026-07-29

Align Technology Q2'26: revenue up 4.3%, Q3 guidance steps down

Align Technology is a Neutral this quarter: revenue of $1.06 billion rose 4.3% year-over-year and gross margin reached 71.7%, but GAAP EPS of $1.51 fell from $1.72 on a UK VAT charge and other items. Non-GAAP EPS of $2.64 came in just below the $2.66 consensus, and the Q3 revenue guide sits under the quarter just reported. Clear aligners are growing; scanner sales are not.

Read the full analysis →
Revenue$1.06BYoY +4.30%
EPS (non-GAAP)$2.64Missest. $2.66
Next-quarter revenue guidance$1.01B ±1%YoY −4.40%
Next-day move−3.70%

Price History

Closing price · USD1M6M1Y5Y
0200400600800EEEEEE2021-102023-012024-042025-082026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 28.31M6M1Y5Y
24262830322026-042026-062026-082026-092026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2027-02-03
in 94 days · After hours
Consensus EPS
$3.26
Last quarter EPS $2.64
Avg. next-day move over the last 6 reports
±9.6%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 11 of its 5-year rangeCheap
5-year range 22.9 – 68.8 · Median 34.7
Last 4 quarters: $267M in buybacks + $0 in dividends, 2.53% of market cap combined
P/E (TTM)
25.6
P/B
2.5
P/S
2.6
PEG
1.36
Earnings Reaction
Over the last 6 reports, the stock moved ±9.6% on average on the first trading day after, rising 3 times
Most recent −3.70%
Guidance Credibility
Of the last 4 next-quarter revenue guides, 3 were met; actual results averaged 0.1% above guidance
Volatility & Correlation
1-year beta 1.29 · Correlation with S&P 500 0.42Tracks the market
Annualized volatility 39% vs. 13% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q21.06+4.3%71.7%0.150.110.161.51
FY2026 Q11.04+6.2%70.8%0.140.110.121.57
FY2025 Q41.05+5.3%65.3%0.160.140.191.88
FY2025 Q31.00+1.8%64.2%0.100.060.170.78
FY2025 Q21.01−1.6%69.9%0.160.120.111.72
FY2025 Q10.98−1.8%69.5%0.130.090.031.27
FY2024 Q41.00+4.0%70.0%0.140.100.261.40
FY2024 Q30.98+1.8%69.7%0.160.120.231.55
FY2024 Q21.03+2.6%70.3%0.150.100.111.28
FY2024 Q11.00+5.8%70.0%0.150.110.021.39
FY2023 Q40.96+6.1%70.0%0.170.120.011.63
FY2023 Q30.96+7.8%69.1%0.170.120.271.58

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView